Aclaris Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).
Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.
Extracted from this filing and checked against the source text.
Andrew Powell resigned as Director at Aclaris Therapeutics, Inc..
On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).View on SEC.gov
Bryan Reasons departed as Director at Aclaris Therapeutics, Inc..
Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.